Larotrectinib
Overview
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRKA, TRKB, and TRKC), indicated for the treatment of solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. It is designed to treat adult and pediatric patients with NTRK fusion-positive tumors regardless of the tumor location.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Larotrectinib expires 16 May 2037. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Larotrectinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.